Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business UpdateGlobeNewsWire • Tuesday
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)GlobeNewsWire • 09/26/24
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary SharesGlobeNewsWire • 09/13/24
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary SharesGlobeNewsWire • 09/11/24
Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy VolunteersGlobeNewsWire • 09/11/24
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy OpportunityInvestors Business Daily • 09/10/24
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy VolunteersGlobeNewsWire • 09/10/24
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)GlobeNewsWire • 08/27/24
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewsWire • 08/21/24
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024GlobeNewsWire • 08/13/24
Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to TradeZacks Investment Research • 07/16/24
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business OfficerGlobeNewsWire • 06/10/24
Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)Zacks Investment Research • 05/28/24
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024GlobeNewsWire • 05/13/24
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary SharesGlobeNewsWire • 04/24/24
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary SharesGlobeNewsWire • 04/23/24
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024GlobeNewsWire • 04/22/24
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023GlobeNewsWire • 03/28/24
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia andGlobeNewsWire • 02/09/24
Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth PotentialSeeking Alpha • 02/05/24